Alerts will be sent to your verified email
Verify EmailINDOCO
Indoco Remedies
|
Unichem Lab
|
Windlas Biotech
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
26.0 . | n/a | n/a |
Global DMFs filed
|
147.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
55.0 . | 41.0 . | n/a |
Number of ANDA's Approved By USFDA
|
30.0 . | 27.0 . | n/a |
Domestic Sales Growth - YoY
|
-4.3 % | n/a | n/a |
R&D as a % of Total Sales
|
6.2 % | 0.94 % | n/a |
Financials
|
|||
5 yr Average ROE
|
9.23 % | -1.8 % | 13.78 % |
5yr average Equity Multiplier
|
1.77 | 1.25 | 1.44 |
5yr Average Asset Turnover Ratio
|
0.91 | 0.39 | 1.07 |
5yr Avg Net Profit Margin
|
5.59 % | -3.43 % | 9.18 % |
Price to Book
|
2.87 | 1.59 | 3.34 |
P/E
|
32.31 | 0.0 | 25.86 |
5yr Avg Cash Conversion Cycle
|
50.62 Days | 134.58 Days | 36.25 Days |
Inventory Days
|
67.15 Days | 136.89 Days | 39.1 Days |
Days Receivable
|
70.89 Days | 147.31 Days | 80.97 Days |
Days Payable
|
140.07 Days | 232.31 Days | 100.63 Days |
5yr Average Interest Coverage Ratio
|
7.2 | -1.13 | 30.38 |
5yr Avg ROCE
|
13.14 % | -1.02 % | 16.11 % |
5yr Avg Operating Profit Margin
|
15.39 % | 5.06 % | 13.43 % |
5 yr average Debt to Equity
|
0.35 | 0.09 | 0.09 |
5yr CAGR Net Profit
|
n/a | 53.41 % | -7.75 % |
5yr Average Return on Assets
|
5.36 % | -1.39 % | 9.49 % |
Shareholdings
|
|||
Promoter Holding
|
58.72 % | 70.22 % | 62.82 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.03 % | 19.29 % | 2.87 % |
Change in Mutual Fund Holding (3 Yrs)
|
-0.83 % | 1.59 % | 1.06 % |
Indoco Remedies
|
Unichem Lab
|
Windlas Biotech
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|